Florence Joly Lobbedez

17PUBLICATIONS
229CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Jan 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Félix Blanc-Durand, Benoit You, Yahia Adnani

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Dec 31, 2025
Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study.

Florence Joly, Claudia Lefeuvre-Plesse, Emilie Charton

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Aug 07, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Mihaela Aldea, Emeline Orillard, Alice Bernard-Tessier

Pageof 3

Frequent Collaborators

7 joint publications

Isabelle Ray-Coquard

5 joint publications

Frédéric Selle

5 joint publications

Coriolan Lebreton

5 joint publications

Eric Pujade-Lauraine